Big Chemical Encyclopedia

Chemical substances, components, reactions, process design ...

Articles Figures Tables About

Ocular pharmacology

P-BLOCKEES timolol Ota-ACONIST brl mo ntdine CA INHIBIT0K5 acetazolamidc dorzolamide O/P AGONIST epinephrine [Pg.26]

RETINOWMV chlorociuine diabetes hypertension high o ygen tension in babies [Pg.26]

The lens (middle lop) provides the adjustable pan of the eye s refractive power. Opacity of the lens is called a cataract. Some drugs, notably eonicosteroids. may cau.se cataracts. [Pg.26]

Tile processes of the ciliary body are highly vascularized and arc the. sites of aqueous humour fonnation. The ciliary epithelial celts, which contain ATPa.se ttnd carbonic anhydrase. absorb Na selectively from the stroma and transpoit it into the intercellular clefts, which open only on the aqueous humour side. I hc hyperosmolality in the clefts causes water How from the stroma, producing a continuous How of aqticou.s. Tlie ciliary epithelium is leaky, allowing signiticam passive liltration, and up to 30% of aqueous may be formed by ulirati It ration. [Pg.27]

The aqueous humour circulate. through the pupil and is drained into the canal of Schlcmm. which is a circular gutter within the. surface of the sclent at the limbus. The sieve-like trabecular meshwork is the roof of the gutter, through which the aqueous must pass before it is eventually drained away into the episcleral veins. [Pg.27]

Jaanus, S. (1984). Anti-inflammatory drugs. In Clinical Ocular Pharmacology (eds. J. Bartlett and S. Jaanus) pp. 153-192, Butterworth, Boston. [Pg.140]

Lee, V.H.L. Robinson, J.R. "Review topical ocular drug delivery recent developments and future challenges" Journal of Ocular Pharmacology, 1986,1,67. [Pg.45]

B. Smith, Handbook of Ocular Pharmacology, Publication Sciences Group, Action, MA, 1974. [Pg.475]

J. D. Bartlett and S. D. Jaanus, Clinical Ocular Pharmacology, Butterworth-Heinemann, 1995, p. 275. [Pg.475]

E Duzman, CC Chen, J Anderson, M Blumenthal, H Twizer. (1982). Diacetyl derivative of nadolol, I. Ocular pharmacology and short-term ocular hypotensive effect in glaucomatous eyes. Arch Ophthalmol 100 1916-1919. [Pg.385]

Hogan RN, Zimmerman GE (1997) Sodimn fluorescein and other tissue dyes. In Zimmerman TJ (ed) Textbook of ocular pharmacology. Lippincott-Raven, Philadelphia, p849... [Pg.29]

Burgalassi, S., Chetoni, P., Panichi, L., Boldrini, E. and Saettone, M.F. (2000b) Xyloglucan as a novel vehicle for timolol pharmacokinetics and pressure lowering activity in rabbits. Journal of Ocular Pharmacology and Therapeutics 16(6), 497-509. [Pg.372]

Generator of NO [272], ocular pharmacology and therapeutics (ocular blood flow, recovery of retinal function after ischemic insult) [273]... [Pg.419]

Mauger TF, Craig EL. Havener s ocular pharmacology, ed. 6. St. Louis, MO Mosby, 1994. [Pg.16]

FisceUa R, Burstein NL. Ophthalmic drug formulations. In Bartlett JD, Jaanus SD, eds. CUmcal ocular pharmacology, ed. 4. Boston Butterworth Heinemann, 2001. [Pg.36]

Yanni JM, Stephens DJ, Miller ST, et al. The in vitro and in vivo ocular pharmacology of olopatadine (AL-4943A), an effective anti-aUergic/antihistaininic agent. J Ocul Pharmacol Ther 1996 12 389-400. [Pg.262]

Lowther, G.E. Preparations used with contact lenses. In Clinical Ocular Pharmacology, 2nd Ed. Bartlett, J.D., Jaanus, S.D., Eds. Butterworth s Boston, 1989 337-353. [Pg.2215]

Havener WH. Ocular Pharmacology. 4th ed. Saint Louis C.V. Mosby, 1978. [Pg.740]

A., et al. (2001) Preclinical efficacy of travoprost, a potent and selective FP prostaglandin receptor agonist. Journal of Ocular Pharmacology therapeutics 17, 421-432. [Pg.66]

Sharif, N. A., Kelly, C. R., Crider, J. Y., et al. (2003) Ocular hypotensive FP prostaglandin (PG) analogs PG receptor subtype binding affinities and selectivities, and agonist potencies at FP and other PG receptors in cultured cells. Journal of Ocular Pharmacology Therapeutics 19, 501-515. [Pg.66]

Bergh, K., Wentzel, P. and Stjemschantz, J. (2002) Production of prostaglandin E2 by iridial melanocytes exposed to latanoprost acid, a prostaglandin F analogue. Journal of Ocular Pharmacology therapeutics, 18, 391 -00. [Pg.67]

Bartlett JD, Jaanus SD. Clinical Ocular Pharmacology. Boston, MA Butterworth-Heinemaim, 1995 275. [Pg.181]

Moroi SE and Lichter PR. Ocular Pharmacology In The Pharmacological Basis of Therapeutics (Limbird LE and Hardman JG, Eds.), 9th Ed., pp. 1619-1645. McGraw-Hill Medical Publishing Division, New York, NY, 1996. [Pg.246]

Ocular pharmacology. 2. Drug delivery systems. 3. Therapeutics, Opthalmological. I. Jaffe, Glenn J. II. Ashton, Paul, 1960- III. Pearson, Andre, 1961-... [Pg.372]

Ocular pharmacology, including consideration of the use of glucocorticoids, is discussed in Chapter 63. [Pg.1035]

See other pages where Ocular pharmacology is mentioned: [Pg.867]    [Pg.475]    [Pg.477]    [Pg.480]    [Pg.286]    [Pg.1]    [Pg.1]    [Pg.3]    [Pg.799]    [Pg.135]    [Pg.266]    [Pg.1714]    [Pg.244]    [Pg.244]    [Pg.164]    [Pg.181]    [Pg.1095]    [Pg.1097]    [Pg.1099]    [Pg.1101]    [Pg.1103]    [Pg.1107]    [Pg.1109]   


SEARCH



© 2024 chempedia.info